Autor(es): Ramos Pinheiro, R ; Diamantino, F ; Cabete, J ; Brasileiro, A ; Baptista, J ; Paiva Lopes, MJ
Data: 2017
Identificador Persistente: http://hdl.handle.net/10400.17/4709
Origem: Repositório do Centro Hospitalar de Lisboa Central, EPE
Assunto(s): HSAC DER; Adolescent; Child; Adalimumab / therapeutic use; Biological Products / adverse effects; Biological Products / therapeutic use*; Humans; Female; Male; Child, Preschool; Dermatologic Agents / adverse effects; Dermatologic Agents / therapeutic use*; Drug Substitution / trends*; Etanercept / therapeutic use; Infliximab / therapeutic use; Psoriasis / drug therapy*; Retrospective Studies; Severity of Illness Index; Ustekinumab / therapeutic use
